From the street to the laboratory: Analytical profiles of methoxetamine, 3-methoxyeticyclidine and 3-methoxyphencyclidine and their determination in three biological matrices

Journal of Analytical Toxicology

Volumn 37, Issue 5, 2013, Pages 277-283

  De Paoli, Giorgia ^a   Brandt, Simon D ^b   Wallach, Jason ^c   Archer, Roland P ^d   Pounder, D J ^a  

^a UNIVERSITY OF DUNDEE   (United Kingdom)

^b LIVERPOOL JOHN MOORES UNIVERSITY   (United Kingdom)

^c UNIVERSITY OF THE SCIENCES   (United States)

^d Longue Rue   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

3 METHOXYETICYCLIDINE; 3 METHOXYPHENCYCLIDINE; METHOXETAMINE; PHENCYCLIDINE; UNCLASSIFIED DRUG;

ARTICLE; BLOOD SAMPLING; CARBON NUCLEAR MAGNETIC RESONANCE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN TISSUE; LIMIT OF DETECTION; LIMIT OF QUANTITATION; MASS FRAGMENTOGRAPHY; PROTON NUCLEAR MAGNETIC RESONANCE; QUANTITATIVE ANALYSIS; TANDEM MASS SPECTROMETRY; URINALYSIS; URINE LEVEL;

CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CYCLOHEXANONES; CYCLOHEXYLAMINES; GAS CHROMATOGRAPHY-MASS SPECTROMETRY; HALLUCINOGENS; HUMANS; PHENCYCLIDINE; PHENCYCLIDINE ABUSE; REPRODUCIBILITY OF RESULTS; STREET DRUGS; SUBSTANCE ABUSE DETECTION; TANDEM MASS SPECTROMETRY;

EID: 84882950488     PISSN: 01464760     EISSN: 19452403     Source Type: Journal    
DOI: 10.1093/jat/bkt023     Document Type: Article

References (32)

1. De Souza, E.B., Clouet, D., London, E.D. (eds.) (1993) Sigma, PCP, and NMDA receptors. NIDA research monograph 133. National Institute on Drug Abuse, Rockville, MD.
2. Jentsch, J.D., Roth, R.H. (1999) The neuropsychopharmacology of phencyclidine: From NMDA receptor hypofunction to the dopamine hypothesis of schizophrenia. Neuropsychopharmacology, 20, 201-225.
3. Morris, B.J., Cochran, S.M., Pratt, J.A. (2005) PCP: From pharmacology to modelling schizophrenia. Current Opinion in Pharmacology, 5, 101-106.
4. Soine, W.H. (1986) Clandestine drug synthesis. Medicinal Research Reviews, 6, 41-74.
5. Carroll, F.I., Lewin, A.H., Mascarella, S.W., Seltzman, H.H., Reddy, P.A. (2012) Designer drugs: A medicinal chemistry perspective. Annals of the New York Academy of Sciences, 1248, 18-38.
6. Wood, D.M., Davies, S., Calapis, A., Ramsey, J., Dargan, P.I. (2011) Novel drugs-Novel branding. QJM, 105, 1125-1126.
7. Hays, P.A., Casale, J.F., Berrier, A.L. (2012) The characterization of 2-(3-methoxyphenyl)-2-(ethylamino)cyclohexanone (methoxetamine). Microgram Journal, 9, 3-17.
8. EMCDDA (2012) EMCDDA-Europol 2011: Annual report on the implementation of Council Decision 2005/387/JHA. EMCDDA/ Europol, Lisbon. http://www.emcdda.europa.eu/publications/ implementation-reports/2011 (accessed 15 September 2012).
9. EMCDDA (2012) Early-warning-system on new drugs. 3-MeO-PCE. European Monitoring Centre for Drugs and Drug Addiction Database on New Drugs (EDND) Cais do Sodré , 1249-289 Lisbon, Portugal.
10. EMCDDA (2012) Early-warning-system on new drugs. 3-MeO-PCP. European Monitoring Centre for Drugs and Drug Addiction Database on New Drugs (EDND) Cais do Sodré , 1249-289 Lisbon, Portugal.
11. Ward, J., Rhyee, S., Plansky, J., Boyer, E. (2012) Methoxetamine: A novel ketamine analog and growing health-care concern. Clinical Toxicology, 49, 874-875.
12. Wood, D.M., Davies, S., Puchnarewicz, M., Johnston, A., Dargan, P.I. (2012) Acute toxicity associated with the recreational use of the ketamine derivative methoxetamine. European Journal of Clinical Pharmacology, 68, 853-856.
13. Hofer, K.E., Grager, B., Müller, D.M., Rauber-Lüthy, C., Kupferschmidt, H., Rentsch, K.M. et al. (2011) Ketamine-like effects after recreational use of methoxetamine. Annals of Emergency Medicine, 60, 97-99.
14. Shields, J.E., Dargan, P.I., Wood, D.M., Puchnarewicz, M., Davies, S., Waring, W.S. (2012) Methoxetamine associated reversible cerebellar toxicity: Three cases with analytical confirmation. Clinical Toxicology, 50, 438-440.
15. Westwell, A.D., Hutchings, A., Caldicott, D.G. (2012) The identification and chemical characterization of a new arylcyclohexylamine, methoxetamine, using a novel emergency department toxicosurveillance tool. Drug Testing and Analysis, 5, 203-207.
16. Abe, E., Ricard, F., Darrouzain, F., Alvarez, J.C. (2012) An automated method for measurement of methoxetamine in human plasma by use of turbulent flow on-line extraction coupled with liquid chromatography and mass spectrometric detection. Analytical and Bioanalytical Chemistry, 405, 239-245.
17. Wikström, M., Thelander, G., Dahlgren, M., Kronstrand, R. (2012) An accidental fatal intoxication with methoxetamine. Journal of Analytical Toxicology, 37, 43-46.
18. Corazza, O., Schifano, F., Simonato, P., Fergus, S., Assi, S., Stair, J. et al. (2012) Phenomenon of new drugs on the Internet: the case of ketamine derivative methoxetamine. Human Psychopharmacology, 27, 145-149.
19. Morris, H. (2011) Interview with a ketamine chemist or to be more precise, an arylcyclohexylamine chemist. Vice Magazine, 18, 98-101.
20. Peters, F.T., Drummer, O.H., Musshoff, F. (2007) Validation of new methods. Forensic Science International, 165, 216-224.
21. Brine, G.A., Williams, E.E., Boldt, K.G., Carroll, F.I. (1979) Carbon-13 nuclear magnetic resonance spectra of phenycyclidine analogs. Journal of Heterocyclic Chemistry, 16, 1425-1429.
22. Brine, G.A., Boldt, K.G., Coleman, M.L., Carroll, F.I. (1984) Carbon-13 nuclear magnetic resonance spectra of phencyclidine analogs substituted in the piperidine and aromatic rings. Journal of Heterocyclic Chemistry, 21, 71-75.
23. Eaton, T.A., Houk, K.N., Watkins, S.F., Fronczek, F.R. (1983) Geometries and conformational processes in phencyclidine and a rigid adamantyl analogue: Variable-temperature NMR, X-ray crystallographic, and molecular mechanics studies. Journal of Medicinal Chemistry, 26, 479-486.
24. Hugel, J., Meyers, J., Lankin, D. (2003) Analysis of the hallucinogens. In Laing, R., Siegel, J.A. (eds.), Hallucinogens: A forensic drug handbook, 1st edition, Chapter X, Academic Press, Amsterdam, The Netherlands, pp. 191-273.
25. Clark, C.C. (1987) The specificity of electron impact mass spectroscopy for the identification of N-ethyl-1-phenylcyclohexylamine (PCE). Journal of Forensic Sciences 32, 917-932.
26. Clark, C.C. (1986) Electron impact mass spectroscopy for identification of phencyclidine. Journal of the Association of Official Analytical Chemists, 69, 814-820.
27. Smith, R.M. (2004) Understanding mass spectra: A basic approach, 2nd edition.Wiley, Hoboken, NJ.
28. Baselt, R.C. (2011) Disposition of toxic drugs and chemicals in man, 9th edition. Biomedical Publications, Seal Beach, CA, pp. 877-880.
29. Vignon, J., Vincent, J.P., Bidard, J.N., Kamenka, J.M., Geneste, P., Monier, S. et al. (1982) Biochemical properties of the brain phencyclidine receptor. European Journal of Pharmacology, 81, 531-42.
30. Chaudieu, I., Vignon, J., Chicheportiche, M., Kamenka, J.M., Trouiller, G., Chicheportiche, R. (1989) Role of the aromatic group in the inhibition of phencyclidine binding and dopamine uptake by PCP analogs. Pharmacology Biochemistry and Behavior, 32, 699-705.
31. Haradahira, T., Sasaki, S., Maeda, M., Kobayashi, K., Inoue, O., Tomita, U. et al. (1998) Synthesis and brain distribution of carbon-11 labeled analogs of antagonists for the NMDA receptor coupled PCP-binding site. Journal of Labelled Compounds and Radiopharmaceuticals, 41, 843-858.
32. Advisory Council on the Misuse of Drugs (ACMD) (2012) ACMD methoxetamine report. http://www.homeoffice.gov.uk/publications/ agencies-public-bodies/acmd1/methoxetamine2012?view=Binary (accessed 27 October 2012).